Last reviewed · How we verify
Amoxycillin
At a glance
| Generic name | Amoxycillin |
|---|---|
| Sponsor | King George's Medical University |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Acute otitis media
- Bacterial pneumonia
- Bacterial urinary infection
- Duodenal Ulcer due to H. Pylori
- E. Coli Genitourinary Tract Infection
- Enterococcus Genitourinary Tract Infection
- Escherichia coli urinary tract infection
- Genitourinary Tract Infection due to Proteus
- Genitourinary Tract Infections
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Chronic Bronchitis
- Haemophilus Influenzae Pharyngitis
- Haemophilus Parainfluenzae Pneumonia
- Haemophilus influenzae pneumonia
- Infection caused by Helicobacter pylori
- Infection due to Escherichia coli
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
Common side effects
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- National Study on Listeriosis and Listeria
- Different Amoxicillin Treatment Regimens in Erythema Migrans Patients (PHASE3)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxycillin CI brief — competitive landscape report
- Amoxycillin updates RSS · CI watch RSS
- King George's Medical University portfolio CI